Abstract:Liver injury is an important complication that may arise in patients suffering from coronavirus disease 2019 (COVID-19) and is accompanied by a transient increase of transaminases and/or other liver enzymes. Liver function test (LFT) abnormalities generally disappear when the COVID-19 resolves or hepatotoxic drugs are discontinued. The LFT abnormalities are associated with drug-induced liver injury (DILI), due to the overuse of antimalarials, antivirals, and antimicrobials. Studies have reported varying levels of these liver injuries in COVID-19 patients; however, most involve elevated serum aminotransferases. Hepatic dysfunction is significantly high in patients with severe illness and has poor outcome. Normally, the liver is involved in the metabolism of many drugs, including nucleoside analogs and protease inhibitors, which are currently repurposed to treat COVID-19. In addition to the manifestation of COVID-19, drugs implemented in its treatment may aggravate liver injuries. Thus, DILI should be considered especially in those COVID-19 patients with underlying liver disease. It was unclear whether the elevated liver enzymes have originated from the underlying disease or DILI in this population. Furthermore, it is difficult to establish a direct relationship between a specific drug and liver injury. Another possible effect of liver damage may due to inflammatory cytokine storm in severe COVID-19. Liver injury can change metabolism, excretion, dosing, and expected concentrations of the drugs, which may make it difficult to achieve a therapeutic dose of the drug or increase the risk of adverse effects. These repurposed drugs have shown limited efficacy against the virus and the disease itself; however, they still pose risk of adverse effects. Careful and close monitoring of LFTs in COVID-19 patients can provide early diagnosis of liver injury, and the risk of DILI could be reduced. Also, drug interactions in liver-transplanted patients should always be kept in mind for certain immunosuppressive therapies and their known signs of DILI. Altogether, abnormal LFTs should not be regarded as a contraindication to use COVID-19 experimental therapies if needed under emergent status.

Liver Injury Caused by Antiviral Agents for COVID-19

Optional Antiviral Agents for the 2019 Novel Coronavirus and the Liver Injury

Liver Injury after Antiviral Treatment of Critically Ill Patients with COVID-19: a Single-Centered Retrospective Cohort Study.

Drug-Induced Liver Disturbance During the Treatment of COVID-19

Liver Diseases in COVID-19: Etiology, Treatment and Prognosis

Liver diseases in COVID-19: Etiology, treatment and prognosis.

Liver Injury in Patients with COVID-19: A Retrospective Study

Impact of Liver Functions by Repurposed Drugs for COVID-19 Treatment

Liver injury in COVID-19: A minireview

COVID-19-associated liver injury: Adding fuel to the flame

Drug-induced liver injury in COVID-19 treatment: Incidence, mechanisms and clinical management

COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management

Liver injury in severe COVID-19 infection: current insights and challenges

Cardiovascular adverse effects of antiviral therapies for COVID-19: Evidence and plausible mechanisms

Pharmacokinetic Interactions Between the Potential COVID-19 Treatment Drugs Lopinavir/ritonavir and Arbidol in Rats

Liver injury in COVID-19: Clinical features, potential mechanisms, risk factors and clinical treatments

Research progress in antiviral therapy for novel coronavirus pneumonia

Corona Virus Disease 2019-Associated Liver Injury in Cold Regions

The effect of antivirals on COVID-19: a systematic review

Recent progress of antiviral therapy for coronavirus disease 2019

COVID-19-associated liver injury, role of drug therapy and management: a review